Briumvi denied by insurance? Appeal and win.
A Briumvi denial is the beginning of a process, not the end of it. This anti-CD20 infusion is most often denied because the plan requires a documented trial and failure of one or more preferred disease-modifying therapies first, or because the prior authorization criteria, hepatitis B screening, and neurologist sign-off were not fully captured in the submission. Appeals that map the patient's history directly onto the plan's own written criteria are frequently overturned.
Reviewed by the Apellica Appeals Team · Updated June 2026
Carrier names and logos are trademarks of their respective owners. Apellica is independent and not affiliated with any insurance carrier or carrier's appeal program.
Briumvi is FDA approved for the treatment of adults with relapsing forms of multiple sclerosis (RMS). This includes clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. It is given as an intravenous infusion: a 150 mg starting dose, a 450 mg dose two weeks later, and then 450 mg every 24 weeks. It is not approved for primary progressive MS or for non-active secondary progressive disease.
Why Briumvi gets denied
- Step therapy not satisfied: the plan requires documented trial and failure, inadequate response, or intolerance to one or more preferred disease-modifying therapies (for example dimethyl fumarate, teriflunomide, fingolimod, glatiramer, or an interferon-beta) before covering Briumvi.
- Non-formulary or non-preferred status: many plans prefer another anti-CD20 agent such as ocrelizumab, so Briumvi is placed off formulary or on a higher tier and requires an exception.
- Prior authorization criteria not documented: missing confirmation of a relapsing-MS diagnosis, prescriber not identified as a neurologist, or no record of required baseline hepatitis B screening and immunoglobulin and liver labs.
- Site-of-care or medical-versus-pharmacy benefit issues: the plan steers IV infusions to a preferred site (home or contracted infusion suite rather than hospital outpatient), or the claim is billed under the wrong benefit.
What a winning appeal includes
- A clear relapsing-MS diagnosis with the supporting ICD-10 code (for example G35), MRI and relapse history, and confirmation that the prescriber is a board-certified or board-eligible neurologist.
- A complete record of prior disease-modifying therapies tried, including drug names, dates, and the specific reason each was stopped (relapse or new MRI activity on therapy, intolerance, or contraindication), which directly answers a step-therapy denial.
- A letter of medical necessity that quotes the plan's own coverage criteria and maps each requirement to the patient's documentation point by point.
- Baseline workup specific to Briumvi: hepatitis B screening (HBsAg and anti-HBc) confirming the patient is not actively infected, plus quantitative immunoglobulins and liver labs, showing the safety prerequisites in the label were met.
How we approach the appeal
First identify which type of denial you have, because the path differs. If Briumvi is non-formulary or non-preferred, file a formulary or tier exception arguing the preferred agent is inappropriate or has already failed. If the denial is a prior authorization or step-therapy denial, appeal on medical necessity and quote the plan's written criteria back to it, attaching documentation for each element it lists. If a preferred drug failed, was not tolerated, or is contraindicated, request a step-therapy override on those grounds and reference any applicable state step-therapy protection law.
Briumvi appeal letter template
Copy this Briumvi appeal letter, fill in the brackets, and send it within your deadline. It is built on what overturns Anti-CD20 monoclonal antibody denials.
[Date] [Your name] · Member ID [ID] · Rx claim # [#] [Insurer or PBM] - Appeals Department Re: Appeal of Briumvi denial I am appealing the denial of Briumvi (ublituximab-xiiy). I request that the denial be overturned and Briumvi approved. 1. The denial. [Insurer] denied Briumvi stating, verbatim: "[paste the exact denial reason from your letter]." 2. Medical necessity. Briumvi is medically necessary for my condition. First identify which type of denial you have, because the path differs. If Briumvi is non-formulary or non-preferred, file a formulary or tier exception arguing the preferred agent is inappropriate or has already failed. If the denial is a prior authorization or step-therapy denial, appeal on medical necessity and quote the plan's written criteria back to it, attaching documentation for each element it lists. If a preferred drug failed, was not tolerated, or is contraindicated, request a step-therapy override on those grounds and reference any applicable state step-therapy protection law. 3. Step-therapy or formulary exception (if that was the reason): I have tried and failed [preferred drug(s)], with pharmacy records attached, or the preferred alternative is contraindicated because [reason]. I request a formulary or step-therapy exception. 4. My request. Approve Briumvi within the timeframe required by law. If the denial is upheld, please provide the specific criteria used, the reviewing clinician's credentials, and external-review instructions. Attached: prescriber letter of medical necessity, pharmacy and prior-trial records, and supporting clinical notes. Sincerely, [Your name]
Want it built and filed for you? Use the free generator, or have Apellica do it.
Internal appeals: 30 days pre-service, 60 days post-service, 72 hours urgent. File within 180 days of the denial.
$0 upfront. We assess fit first, then build and file the appeal for you.
- · The denial letter and your Explanation of Benefits (EOB)
- · Insurance ID, plan name, and the claim or prior-authorization number
- · Diagnosis with ICD-10 code and the prescriber's clinical notes
- · A record of treatments already tried and how they worked
Appealing a Briumvi denial by insurer
The path depends on who manages your benefit. The most common:
Coverage runs through the pharmacy benefit. Appeal the coverage determination and, when the drug is non-formulary, file a formulary or tier exception with a provider attestation that covered alternatives are unsuitable.
Publishes detailed prior-authorization criteria. A denial usually means a criterion was not documented. Appeal through a coverage review, with a formulary exception for excluded drugs.
Administers many UnitedHealthcare and employer plans. Appeals and exceptions follow the plan's published PA criteria; expedited review exists for urgent cases.
Internal appeal first, then independent external review. Pre-service decisions are generally made within 30 days, urgent within 72 hours.
Internal appeals and external review; pharmacy denials often route through OptumRx criteria.
Independent state plans, so criteria vary. Match the appeal to your specific BCBS plan, internal appeal first, then external review.
Frequently asked questions
My plan wants me to try another MS drug first. Do I have to fail it before I can get Briumvi?
Often the plan requires a documented trial of a preferred disease-modifying therapy before covering Briumvi, but you can request a step-therapy override. If you already tried and failed a comparable drug, had an inadequate response, could not tolerate it, or it is medically contraindicated for you, document that clearly and ask for the exception. Many states also have step-therapy protection laws your neurologist can cite.
My insurer prefers Ocrevus instead of Briumvi. Can I still get Briumvi covered?
Yes. When a plan prefers a different anti-CD20 agent, you file a formulary or tier exception. The appeal is strongest when your neurologist explains why Briumvi is the appropriate choice for you, for example a prior reaction or inadequate response to the preferred agent, or a clinically relevant difference such as the shorter one-hour maintenance infusion. Tie the reasoning to the plan's exception criteria.
Why does my insurer want hepatitis B test results before approving Briumvi?
Briumvi carries a boxed warning for hepatitis B virus reactivation, and the FDA label requires hepatitis B screening before the first dose. Plans mirror that in their prior authorization criteria. Submitting your HBsAg and anti-HBc results, along with baseline immunoglobulin and liver labs, shows the safety prerequisites were met and removes a common reason these requests are held up or denied.
Briumvi denied? We fight it for you.
$0 upfront. Two-minute intake. We confirm fit and reply within one business day with the right path for your situation.
Start Your AppealThis page provides general information about appeal strategy. It is not legal or medical advice. Apellica is not a law firm. Outcomes depend on documentation, plan terms, and timing.